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ervical cancer is the second 
most common cancer in 
women and a leading cause 
of mortality worldwide, with 273,000 
deaths estimated in 2002 [1]. Eighty-
three percent of cases occur in the 
developing world, where cervical 
cancer accounts for 15% of female 
cancers, as compared to just 3.6% in 
developed countries [1]. 
In the 1960s and 1970s, incidence 
rates in high-income countries were 
similar to those seen in the developing 
world today; the subsequent decline 
in cervical cancer incidence and 
mortality in high-income countries is 
largely credited to effective screening 
programs [2–11]. Considerable debate 
has arisen about whether such strategies 
are feasible and cost-effective in the 
developing world, where most cervical 
cancer now occurs [12–16]. 
Country-level data on current levels 
of screening provide important input 
into the debate on global cervical 
cancer policy planning. While there 
has been extensive research on rates of 
screening in the United States and other 
industrialized nations [17–22], data 
from the developing world are limited to 
a few countries and sub-national surveys 
[14,23–27]. In addition, the magnitude 
of inequalities in screening is virtually 
unknown in all but a few countries 
[28–30]. Differences in current levels 
of access to screening may have 
implications for designing screening 
and prevention strategies, particularly 
given novel approaches for screening 
and treatment in low-income settings 
[31–38], as well as for the development 
and delivery of a vaccine against the 
strains of human papillomavirus (HPV) 
that cause cervical cancer [39–52]. 
While cervical cancer programs also 
require human resources and laboratory 
infrastructure, the World Health 
Organization has identified screening 
coverage as a crucial component of 
providing effective prevention [53]. It 
is also the component of programs least 
amenable to purely financial solutions, 
unlike purchasing equipment, training 
employees, or ensuring laboratory 
quality control.
In this paper we present estimates 
of the average level and inequalities 
in cervical cancer screening from 57 
countries across all levels of economic 
development included in the World 
Health Surveys (WHS), a set of 
household surveys implemented by 
the World Health Organization in 
2002 [54]. More details on the surveys 
are provided in Table S1. We define 
the population eligible for screening 
as women aged 25 to 64, although 
Figure S1 shows that our results 
are robust across definitions of the 
eligible population. We show results 
for two measures: (1) crude coverage, 
which we define as the proportion of 
eligible women who report that they 
have had a pelvic exam (regardless 
of when the exam occurred), and (2) 
effective coverage, which we define 
as the proportion of eligible women 
who report that they have had a pelvic 
exam and Pap smear in the past three 
years. We calculate coverage by global 
wealth deciles, which are comparable 
across countries, as well as by a relative 
wealth index specific to each individual 
country. More specific details of the 
Coverage of Cervical Cancer Screening in 57 
Countries: Low Average Levels and Large 
Inequalities
Emmanuela Gakidou*, Stella Nordhagen, Ziad Obermeyer
Funding: Funding for this study was provided by the 
Bill & Melinda Gates Foundation Grand Challenges in 
Global Health. The funders had no role in the analysis 
of the data, drafting of the manuscript, or decision 
to publish. 
Competing Interests: The authors have declared 
that no competing interests exist.
Citation: Gakidou E, Nordhagen S, Obermeyer Z 
(2008) Coverage of cervical cancer screening in 57 
countries: Low average levels and large inequalities. 
PLoS Med 5(6): e132. doi:10.1371/journal.
pmed.0050132
Copyright: © 2008 Gakidou et al. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, 
and reproduction in any medium, provided the 
original author and source are credited.
Abbreviations: HPV, human papillomavirus; WHS, 
World Health Surveys
Emmanuela Gakidou, Stella Nordhagen, and Ziad 
Obermeyer are at the Institute for Health Metrics 
and Evaluation at the University of Washington, 
Seattle, Washington, United States of America. Ziad 
Obermeyer is also at Harvard Medical School, Boston, 
Massachusetts, United States of America.
* To whom correspondence should be addressed. 
E-mail: gakidou@u.washington.edu
Summary Points 
sÈ 4HEÈLARGEÈDECLINESÈINÈCERVICALÈCANCERÈ
mortality in developed countries 
have been attributed to widespread 
screening, but it is unclear whether 
this success can be replicated in the 
developing world.
sÈ )TÈISÈGENERALLYÈASSUMEDÈTHATÈSCREENINGÈ
coverage in the developing world is 
low; in this paper we substantiate this 
claim with evidence from 57 countries, 
thus contributing to the evidence base 
for formulation of effective policies.  
sÈ /URÈANALYSISÈOFÈPOPULATION
BASEDÈ
surveys indicates that coverage 
of cervical cancer screening in 
developing countries is on average 
19%, compared to 63% in developed 
countries, and ranges from 1% in 
Bangladesh to 73% in Brazil.
sÈ /LDERÈANDÈPOORÈWOMENÈWHOÈAREÈATÈ
the highest risk of developing cervical 
cancer, are least likely to be screened. 
sÈ 3TRATEGIESÈFORÈIMPROVINGÈCERVICALÈ
cancer prevention must be adapted to 
meet the specific needs of individual 
countries: expanded screening may 
be a viable option where sufficient 
infrastructure and health system 
access exists, but novel strategies need 
to be considered in other settings. 
The Policy Forum allows health policy makers around 
the world to discuss challenges and opportunities for 
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parameters and methods used for this 
analysis are provided in Text S1.
For the majority of these countries, 
these data represent the only 
information available on coverage of 
cervical cancer screening. This analysis 
points to an acute shortage of cervical 
cancer prevention services across 
much of the developing world and 
striking inequalities in access to these 
services, highlighting the need for new 
prevention and treatment strategies. 
Our Findings
Figure 1 shows levels of coverage of 
cervical cancer screening for the 57 
countries, and Table 1 summarizes 
these results. The population-weighted 
means of crude coverage and effective 
coverage of cervical cancer screening 
across all included countries are 
68% and 40%, respectively. In the 30 
developing countries surveyed, these 
rates are much lower: 45% and 19%, 
respectively. (Former communist 
countries are considered developed 
for purposes of this analysis.) There is 
wide variation in the level of effective 
coverage across countries, from over 
80% in Austria and Luxembourg to 
1% or less in Bangladesh, Ethiopia, 
and Myanmar. In many countries, a 
large proportion of women have had 
pelvic examinations, but the exam was 
not accompanied by laboratory tests 
or was not done in the three years 
preceding the survey. In Georgia, for 
example, 67% of women have had a 
pelvic exam, but only 11% had had 
one in the preceding three years and 
accompanied by a Pap smear; likewise 
in China, crude coverage is 70%, 
but effective screening coverage is 
only 23%. (Estimates of coverage by 
age group and wealth quintile for all 
included countries are provided in 
Table S2.)
In a large number of countries the 
majority of women have never had a 
pelvic exam. This proportion is largest 
in Malawi, Ethiopia, and Bangladesh, 
where more than 90% of women report 
that they have never had a pelvic exam. 
In 16 of the 57 countries analyzed, 
more than half of eligible women had 
never had a pelvic exam. Figure 1 also 
demonstrates that the relationship 
between the proportion of women 
ever having a pelvic exam and the 
proportion effectively screened is not 
uniform. Even among high-income 
countries, which have crude coverage 
rates at or above 90%, the proportion 
of women who are effectively screened 
varies widely. 
Figure 2 shows crude and effective 
coverage of cervical cancer screening 
across age groups for developed 
and developing countries. While the 
age pattern of crude and effective 
coverage is similar across level of 
development, coverage is markedly 
lower in developing countries. Crude 
and effective coverage rates begin to 
decline for women over 45 years of age 
in developing countries and over 55 
years of age in developed countries. 
The age group at which the declines 
in effective coverage are observed 
corresponds with the age at which 
doi:10.1371/journal.pmed.0050132.g001 
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incidence rates and mortality from 
cervical cancer have been shown to rise 
sharply [53].
Figure 3 shows that considerable 
inequalities in crude and effective 
coverage of cervical cancer screening 
exist across global wealth deciles. 
While the average crude screening 
rate across the set of countries in the 
analysis was 68%, only 31% of women 
in the poorest global wealth decile have 
ever had a pelvic exam, compared to 
91% of women in the richest global 
wealth decile. The inequalities are 
even more pronounced for effective 
coverage of cervical cancer screening, 
with the poorest women being nearly 
seven times less likely to have been 
screened effectively compared to 
their rich counterparts (9% and 64%, 
respectively). Even though crude 
coverage rates are high for women in 
the richest wealth deciles, effective 
coverage rates are overall very low: all 
wealth deciles except the wealthiest 
have effective coverage rates of lower 
than 60%, and effective coverage of 
cervical cancer screening is at or below 
10%  in the poorest three deciles.
In addition to inequalities across 
countries, significant wealth-related 
inequalities also exist within countries. 
Figure 4 demonstrates inequalities 
between the poorest and richest 
quintiles in crude and effective 
screening coverage for Brazil, China, 
Germany, and India, four of the most 
populous countries included in the 
WHS. We present results using a within-
country relative wealth index; while not 
directly comparable across countries, 
it is more relevant for within-country 
inequalities. In India, the rates of 
coverage are very low for rich and poor 
women alike. While crude coverage 
for rich women is higher (36% 
compared to 22% for poor women), 
effective coverage for cervical cancer 
screening is uniformly low, 6% and 4% 
respectively. By contrast, wealth-related 
inequalities are very pronounced for 
both crude and effective coverage in 
China and Brazil. In Germany, as in 
several other high-income countries, 
crude coverage rates are uniformly 
high, and therefore wealth-related 
inequalities are mainly observed for 
effective coverage of cervical cancer 
screening. 
Policy Implications
The results of this study illustrate that 
a wide range of current screening 
practices exists across countries; this 
makes it unlikely that any one strategy 
will prove to be effective globally. 
Choices regarding cervical cancer 
prevention strategies must be adapted 
to the current situation and the 
constraints of individual countries—
indeed, multiple strategies may need to 
be pursued within the same country. In 
this regard, it may be useful to consider 
countries in three broad groups, 
based on current screening coverage 
rates, each facing different policy 
choices with regard to cervical cancer 
prevention. 
In developed countries, where high 
rates of effective coverage have been 
achieved, focusing on the subgroups 
of women who are not effectively 
screened may be a reasonable and cost-
effective strategy. It is likely that HPV 
vaccination would lead to some health 
gains in these countries; however, 
the benefits of this strategy should be 
weighed against its substantial costs. 
In some middle-income and former 
communist countries, a majority 
of women have had pelvic exams 
in their lifetime; however, rates of 
effective screening (i.e., a recent 
doi:10.1371/journal.pmed.0050132.g002 
Figure 2. Coverage of Cervical Cancer Screening, By Age Group, Across Two Development Groups
Table 1. Crude and Effective Cervical Cancer Screening Coverage across Development 
Groups for Women Ages 25–64 (With 95% Confidence Intervals)
Development Group Crude Coverage Effective Coverage
Developed countries 93.6% (93.2%–94.0% 18.5% (18.3%–18.8%)
Developing countries 44.7% (44.4%–45.1% 18.5% (18.3%–18.8%
All countries 67.9% (67.6%–68.2%) 39.6% (39.3%–40.0%)
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exam accompanied by laboratory 
tests) are low. This indicates that a 
large proportion of women in these 
countries have contact with obstetric 
or gynecologic health services, and 
that the health system may have the 
capacity to provide effective screening 
to a larger number of women. In these 
countries, it may be possible to build 
on “missed opportunities”—pelvic 
exams without laboratory tests or of 
insufficient frequency—to increase 
coverage without significant investment 
in health infrastructure. “Organized” 
programs, with systematic call, recall, 
follow-up, and surveillance, hold 
promise in this regard [13] and could 
be implemented in the context of 
existing health services. 
This study also identifies a number 
of countries where the vast majority of 
women have never had a pelvic exam. 
In such settings, where the health 
system is unable to provide even low 
levels of crude coverage of this basic 
intervention, improved screening is 
clearly urgent, especially for women 
aged over 35 years. Visual inspection 
with acetic acid has recently shown 
promise as an appealing alternative to 
cytological examination in low-income 
settings: overall cost is lower, and 
women in need of further intervention 
can be identified immediately rather 
than after laboratory results are 
obtained [55]. It is also clear that 
improving women’s access to the 
health system should be a high priority, 
as contact with the health system is a 
prerequisite for any screening program 
to succeed. 
More radical solutions, however, 
may be needed, particularly for 
this latter group of countries. The 
availability of a vaccine for HPV offers 
one such solution. Vaccination places 
considerably fewer logistical demands 
on a health system than repeated 
screening, testing, and treatment of 
precursor lesions. In addition, it may 
be easier to reach younger women 
than to systematically screen older 
women, who are at the highest risk of 
developing cervical cancer. In some 
of these countries, for example the 
Philippines, where school enrolment 
rates are relatively high, vaccination 
programs could be implemented 
in the context of the education 
system. Such an approach would 
be substantially less expensive and 
easier to implement than delivering 
the vaccine through door-to-door 
approaches or through primary health 
care, where population coverage levels 
are likely to be low. Donors may also 
be more prepared to pay for targeted 
interventions like vaccines, which can 
easily be implemented through vertical 
programs. Finally, it is possible that 
vaccination may be more culturally 
acceptable than vaginal examination in 
some cultures with the lowest rates of 
coverage.
However, the benefits of the vaccine 
must be weighed against its limitations 
as a prevention strategy as well as its 
considerable cost. Vaccination will not 
have an impact for many years, as it has 
to be directed to adolescents before the 
onset of sexual activity. The immediate 
need for cervical cancer screening and 
control in many developing countries 
suggests that there should be greater 
emphasis on strategies to reach women 
aged 35 or over, while alternatives are 
being considered and explored. The 
current version of the HPV vaccine 
protects against the two strains most 
commonly implicated in cervical 
cancer. Since the vaccine is projected 
to prevent the majority of, but not all, 
cervical cancer cases, screening will 
likely still need to be recommended 
for vaccinated women. There is also 
the possibility that a new emphasis on 
a vaccine would divert resources and 
attention—at the policy level as well as 
for individual women—from screening 
[38]. 
In addition, the cost of purchasing 
the vaccine may be significant. A recent 
study showed that vaccination and 
three screening visits would be very 
cost-effective, assuming a total cost of 
vaccination of US$25 per woman.[56]. 
However, the current cost of the 
vaccine is very far from this projection: 
while there may be opportunities for 
international programs to negotiate 
discounts through mass purchasing 
[57,58], the current price of US$300–
US$400 per course [59,60] may be 
prohibitive. Indeed, the real cost may 
be higher, since women would need 
to be reached multiple times in order 
to deliver each dose of a multiple-
dose course [56] and since cold-chain 
infrastructure is currently required. 
Since vaccination does not obviate 
the need for screening, the financial 
burden of both strategies may be too 
high for already strained health systems 
to bear. An addition consideration 
to keep in mind, highlighted by the 
recent controversy over the vaccine in 
the US [61], is that vaccinating women 
against a sexually transmitted infection 
is by no means universally culturally 
accepted. 
Finally, this study also highlights the 
urgent need for better monitoring of 
cervical cancer screening and control 
and for in-depth evaluations of current 
strategies implemented in various 
countries, so that the evidence base of 
doi:10.1371/journal.pmed.0050132.g003 
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what works and what does not can be 
strengthened. Questions on preventive 
services, including cervical cancer and 
breast cancer screening, are often not 
included in national health surveys in 
developing countries, thus resulting 
in a weak global evidence base for 
cervical cancer screening and control. 
The World Health Surveys, which 
were used in this analysis, have several 
limitations. First, among the limitations 
of self-reported data is the fact that, for 
questions on cervical cancer screening, 
it is difficult to know with certainty 
whether we are measuring the coverage 
of a pelvic exam in the context of 
obstetric or gynecologic care or a 
screening test for cancer. Also, while it 
is likely that women would remember a 
pelvic exam, our estimates of effective 
coverage are limited by the ability of 
women to report whether a laboratory 
test (i.e., a Pap smear) was performed 
in the context of the pelvic exam. Since 
it is possible that a number of women 
were not informed, did not understand, 
or did not report this test, our numbers 
may represent a low estimate of 
effective coverage. It is also possible 
that women do not report accurately 
on the timing of the vaginal exam and 
that our estimates of crude coverage are 
underestimates, if women do not report 
vaginal exams that were performed 
several years before the survey. 
We have attempted to correct for 
bias from missing data by applying a 
multiple imputation method; however, 
this technique may not adequately 
address all the bias in the WHS data. 
Despite these limitations, the WHS 
provide the first opportunity to 
estimate cervical cancer screening rates 
and inequalities across a large set of 
developing and developed countries. 
The findings presented in this paper 
provide a solid starting point, while 
highlighting the need to improve 
the quality and the frequency of 
monitoring of cervical cancer screening 
and control efforts worldwide.
Conclusion
Effective coverage rates for cervical 
cancer screening services are very 
low outside of developed countries, 
and women at the highest risk of 
developing cervical cancer are 
among the least likely to be screened. 
Coverage rates decline with advancing 
age, when cervical cancer incidence 
rates are the highest. Poor women, who 
likely have higher exposure to known 
cervical cancer biological risk factors 
such as smoking and unsafe sex [62], 
also show much lower coverage rates. 
Improving the effective coverage of 
cervical cancer screening or developing 
alternative ways to decrease cervical 
cancer mortality worldwide would have 
a considerable impact on decreasing 
the disease’s burden as well as overall 
health inequalities. No one strategy will 
work everywhere, making it important 
to consider multiple strategies across—
and likely within—countries.  
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